Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 109, Issue 5, Pages 1256-1264Publisher
WILEY
DOI: 10.1002/cpt.2078
Keywords
-
Categories
Funding
- Robert Bosch Stiftung, Stuttgart, Germany
- European Union Research and Innovation Program Horizon 2020 grant [U-PGx 668353]
Ask authors/readers for more resources
CYP2D6 metabolizes a significant portion of clinically used drugs, with its genetic polymorphism playing a key role in drug safety and efficacy. The study identified specific genetic variants causing functional differences between the common alleles *2 and *41, highlighting the importance of considering triple haplotypes in explaining these differences for clinical implementation of CYP2D6 pharmacogenetics.
CYP2D6 metabolizes 20-25% of all clinically used drugs and its complex genetic polymorphism is a major determinant of drug safety and efficacy. We investigated the basis for the functional difference between the two common alleles *2 (g.2851C>T + g.4181G>C, normal function) and *41 (additional intronic g.2989G>A, reduced function). A recently reported far-distant enhancer polymorphism rs5758550A/G linked to *2 has been suggested to play a decisive role. Genotyping of two white cohorts confirmed strong linkage of rs5758550G to *2, whereas no influence was found on metabolic ratio of sparteine or hepatic expression. Genomic plasmid constructs carrying individual variants or combinations thereof were expressed in COS1 and Huh7 cells. Both g.2851C>T(R296C) and g.2989G>A reduced enzyme activity and protein levels similarly by similar to 50-65% compared to reference (*1), whereas the double variant had only similar to 20% activity. Although the unexpected loss of function caused by g.2851C>T was compensated by g.4181G>C (mimicking the EM-phenotype of *2), the additional loss of function due to intronic g.2989G>A in the triple variant was not compensated (mimicking the IM-phenotype of *41). We also confirmed increased erroneous splicing in carriers of g.2989G>A but not of g.2851C>T as a likely explanation for the impaired function of *41. In conclusion, our data demonstrate g.2989G>A as causal variant of impaired allele CYP2D6*41 whereas triple-haplotypes have to be considered to explain the functional difference between *2 and *41. These data are important for genotyping strategies and clinical implementation of CYP2D6 pharmacogenetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available